Imaging Shared Resource

项目摘要-为共享资源创建映像 影像共享资源(ISR)的主要目标是为Wistar研究所癌症中心成员 具有全面而灵活的成像解决方案，从高端显微镜到小动物 完成图像成像分析服务。近年来，技术的进步使我们有可能 利用定量、高分辨率成像方法剖析细胞行为的时空方面 与恶性转化、转移转移和治疗反应有关，而ISR具有 充分定位以支持对这些领域的调查。在上一个预算周期中，ISR进一步 加强了新的科学领导，增加了人员，并显著扩展了新的 仪器仪表和设施翻新。ISR继续提供基本的宽视场、直立和倒置 显微镜，以及用于常规应用的低放大和标本成像，但也投资了 在新的徕卡SP8X WLL白光扫描共聚焦显微镜中补充现有的徕卡SP5 共焦。这些系统结合在一起，满足了日益增长的对先进显微镜在 癌症中心。这一新仪器针对高分辨率、快速、活细胞成像进行了优化，并提供了 该仪器需要成功地研究多个细胞内的动态机制 尺寸。此外，一台新的徕卡SP8 MP 2光子活体内显微镜已经取代了过时的 Prairie Instruments型号，不仅能够在两种模式下提供单次会话、深度成像支持 活体和固定模型，以及对活体小鼠转移生长和肿瘤形成的纵向研究 模特们。尼康领带倒置宽视场系统也被添加到设施中，特别适用于高度 自动成像，包括大面积拼接获取载玻片和平板。领带已完全配置为 高内容、延时记录，用于连续、实时的图像分析。以进一步支持 用于询问转移进展和反应的活体小鼠模型的纵向成像研究 对于靶向治疗，ISR申请并获得了S10共享仪器赠款(S10 OD021669) 用于购买新的Perkin Elmer IVIS SpectrumCT小动物成像系统。这台新仪器 替换了较旧的IVIS 200，并以集成的MicroCT单元的形式添加了新的功能 为更准确地定位和测量肿瘤负荷提供了3D定量机会。高度的 经验丰富的员工直接与用户合作获取他们的图像，或培训用户操作设备 独立的。ISR专门支持复杂的多模式成像实验，包括FRAP， 利用3D跟踪的FRET和6D项目。ISR强调在形象的各个方面进行道德实践 采集、后处理图像处理和分析。ISR的总体任务是帮助癌症 中心研究人员对引发恶性转化的事件进行可视化和分析，目标是 改善癌症诊断，以及开发新的、更好的治疗剂。

PROJECT SUMMARY – IMAGING SHARED RESOURCE The primary goal of the Imaging Shared Resource (ISR) is to provide Wistar Institute Cancer Center members with comprehensive and flexible imaging solutions, ranging from high-end microscopy and small animal imaging to complete image analysis services. In recent years, technological advances have made it possible to utilize quantitative, high resolution imaging approaches to dissect spatio-temporal aspects of cellular behavior related to malignant transformation, metastatic dissemination, and therapeutic response, and the ISR has amply positioned itself to support inquiries into these areas. During the last budget cycle, the ISR was further enhanced with new scientific leadership, additional personnel and a significant expansion of new instrumentation and facility renovations. The ISR continues to offer basic widefield, upright and inverted microscopy, as well as low magnification and specimen imaging for routine applications, but has also invested in a new Leica SP8X WLL white-light scanning confocal microscope to complement an existing Leica SP5 confocal. Combined, these systems respond to an increasing need for advanced microscopy usage within the Cancer Center. This new instrument is optimized for high resolution, rapid, live-cell imaging and has provided the instrumentation needed to successfully investigate dynamic, intracellular mechanisms in multiple dimensions. Additionally, a new Leica SP8 MP 2-Photon, intravital microscope has replaced an obsolete Prairie Instruments model and is capable of providing not only single session, deep imaging support in both live and fixed models, but also longitudinal studies of metastatic growth and tumorigenesis in live mouse models. A Nikon TiE inverted widefield system was also added to the facility and is especially useful for highly automated imaging including large area stitched acquisition of slides and plates. The TiE is fully configured for high-content, time-lapse recording and is set up for continuous, real-time image analysis. To further support longitudinal imaging studies in live mouse models designed to interrogate metastatic progression and response to targeted therapies, the ISR applied for, and was awarded an S10 shared instrument grant (S10 OD021669) for the purchase of a new Perkin Elmer IVIS SpectrumCT small animal imaging system. This new instrument replaced an older IVIS 200 and adds new functionality in the form of an integrated microCT unit as well as quantitative opportunities in 3D for more accurate localization and measurement of tumor burden. The highly experienced staff works directly with users to acquire their images, or trains users to operate equipment independently. The ISR specializes in supporting complex, multimodal imaging experiments including FRAP, FRET and 6D projects utilizing 3D tracking. The ISR stresses ethical practices in all aspects of image acquisition, post-process image manipulation and analysis. The overall mission of the ISR is to assist Cancer Center researchers in visualizing and analyzing events that initiate malignant transformation with the goal of improving cancer diagnosis, and the development of new, better therapeutic agents.